"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
| Descriptor ID |
D006918
|
| MeSH Number(s) |
D02.948.395
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".
This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2004 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 3 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 0 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Protection against vancomycin-associated nephrotoxicity by zileuton: role of mitochondria revealed by electron microscopic study. Ultrastruct Pathol. 2025; 49(5):414-420.
-
Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicity. Antimicrob Agents Chemother. 2025 08 06; 69(8):e0028725.
-
Engaging Parents of Children With Sickle Cell Disease in Shared Decision-Making for Hydroxyurea: The ENGAGE-HU Study. Pediatr Blood Cancer. 2025 May; 72(5):e31639.
-
Splenic complications in pediatric sickle cell disease: A retrospective cohort review. Pediatr Blood Cancer. 2024 Oct; 71(10):e31219.
-
Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies. J Pediatr Hematol Oncol. 2024 07 01; 46(5):e277-e283.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Biallelic variants in CRIPT cause a Rothmund-Thomson-like syndrome with increased cellular senescence. Genet Med. 2023 07; 25(7):100836.
-
Hyperextended telomeres promote formation of C-circle DNA in telomerase positive human cells. J Biol Chem. 2023 05; 299(5):104665.
-
Screening for asthma in preschool children with sickle cell disease. J Asthma. 2023 09; 60(9):1787-1792.
-
Pediatric Sickle Cell Disease Patients on Hydroxyurea Have Higher Rates of Surgical Splenectomy. J Surg Res. 2023 Mar; 283:798-805.